Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Clinical trial NCT07075016 · RECRUITING
Trial details
- NCT number
- NCT07075016
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-05
- Primary completion
- 2028-12-01
- Enrollment
- 227
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.